The latest rejection looks set to mark the end of J&J's drive to resolve the litigation through the bankruptcy courts, as the ...

Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, according to a new study, which also suggests ...

With the world braced for an announcement of sweeping tariffs later today by President Donald Trump, analysts at ING have ...

Prosecutors in the US are seeking the death penalty for Luigi Mangione, the man detained in connection with the assassination ...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an ...

Under Kennedy's plan, the FDA is set to bear the brunt of the job losses, with 3,500 workers due to be shed, while the CDC is ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...

At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock sat down with Dr Michael Bauer, CEO of Quantro Therapeutics, ...

That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting, which found ...

EVERSANA – pharmaphorum's parent company – said it has met the standard to join Veeva's partner programme and will now be ...

Eli Lilly's direct-to-consumer platform LillyDirect has been expanded to include in-person and telehealth services for people ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...